Maternal Docosa-Hexanoic Acid (DHA) Supplementation and Offspring Neurodevelopment in India (DHANI-2) - DHANI-2

The Wellcome Trust DBT India Alliance0 个研究点目标入组 957 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. 18-35 y old pregnant women (singleton) at <20 weeks of gestation (calculated from the last menstrual period or by ultrasound in 1st trimester as suggested by study physician/team).
•2. Willing to participate in the study and provide all measurements for her and the offspring including anthropometry, dietary assessment and questionnaires plus the biochemical parameters (blood, breast milk)
•3. Witnessed informed consent signed by mother.

•1. Women allergic (if aware) to any of the test products.
•2. Women with any known history of bleeding tendency or thrombosis (if aware).
•3. Women with high-risk pregnancies â??
•- any bleeding episode in the current pregnancy;
•- hypertension;
•- diagnosed heart disease;
•- diabetes
•4. Women consuming omega-3 supplements or having used these in 3 months preceding the intervention period.
•5. Reported participation in another biomedical trial 3 months before the start of the study or during the study (not to get the results of the present study contaminated).

发起方